Presentation of Data from Clinical Trial of

临床试验数据的展示

Aspen's

阿斯彭的

Autologous iPSC-derived Approach for Neuronal Replacement Therapy in Parkinson's Disease

帕金森病神经元替代疗法的自体iPSC衍生方法

SAN DIEGO

圣地亚哥

,

，

June 9, 2025

2025年6月9日

/PRNewswire/ -- Aspen Neuroscience, Inc. announced its participation in 'Illuminating the Future,' the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, to be held in

/PRNewswire/ -- Aspen Neuroscience, Inc. 宣布将参与“Illuminating the Future”——国际干细胞研究学会（ISSCR）2025年年会，会议将于

Hong Kong

香港

June 11-14

6月11日至14日

.

。

Aspen Co

阿斯彭公司

-founder and Senior Vice President, Research and Development, Andrés Bratt-Leal, PhD will deliver a presentation,

-创始人兼研发高级副总裁安德烈斯·布拉特-利尔博士将发表演讲，

Safety, tolerability, and efficacy of transplanted autologous iPSC-derived dopaminergic precursors in moderate to advanced Parkinson's Disease

中度至重度帕金森病患者移植自体iPSC衍生的多巴胺能前体细胞的安全性、耐受性和有效性研究

.

。

Dr. Bratt-Leal's presentation will cover data for the first four patients of the ASPIRO Study*, a Phase 1/2a trial of the company's iPSC-derived autologous cell therapy (ANPD001). The open label trial was designed to evaluate the safety, tolerability and efficacy of intracranial implantation of autologous induced pluripotent stem cell (iPSC)-derived dopaminergic neuronal precursor cells (DANPCs) in patients with moderate to advanced Parkinson's disease..

布拉特-李博士的演讲将涵盖ASPIRO研究*的前四名患者的数据，这是一项关于该公司iPSC衍生的自体细胞疗法（ANPD001）的1/2a期试验。这项开放标签试验旨在评估颅内植入自体诱导多能干细胞（iPSC）衍生的多巴胺能神经前体细胞（DANPCs）在中度至重度帕金森病患者中的安全性、耐受性和有效性。

The primary objective of the ongoing study is to assess safety and tolerability of the procedure. A secondary objective is to evaluate clinical efficacy as measured by change from baseline in multiple patient-reported and clinician-reported Parkinson's disease outcome measures. Continued follow up and evaluation of a higher-dose cohort in the study are ongoing..

当前研究的主要目标是评估该程序的安全性和耐受性。次要目标是通过多种患者报告和临床医生报告的帕金森病结果指标从基线的变化来评估临床疗效。对更高剂量组的持续随访和评估仍在进行中。

'Early data from the first four patients show that precision intracranial delivery of DANPCs is safe and well-tolerated,' reported Dr. Bratt-Leal. 'Both patient-reported and clinician-reported outcomes show early signs of changes from baseline in multiple clinically meaningful outcome measures. Autologous iPSC-derived therapy as a regenerative medicine approach has the unique advantage of not requiring immunosuppressive medications.'.

“前四名患者的早期数据显示，DANPCs 的精准颅内递送是安全且耐受性良好的，”布雷特-李尔博士报告称。“患者报告和临床医生报告的结果均显示，在多项有临床意义的指标中，较基线水平出现了早期变化迹象。自体 iPSC 衍生疗法作为一种再生医学方法，具有无需使用免疫抑制药物的独特优势。”

About Aspen Neuroscience

关于Aspen神经科学

Headquartered in San Diego, Aspen Neuroscience, Inc. is a clinical development-stage, private company focused on autologous regenerative medicine. The company's patient-derived iPSC platform is used to create personalized therapies to address diseases with high unmet medical needs, beginning with autologous neuron replacement for PD. .

总部位于圣地亚哥的阿斯彭神经科学公司是一家处于临床开发阶段的私营公司，专注于自体再生医学。该公司利用患者衍生的诱导多能干细胞（iPSC）平台来开发个性化疗法，以应对具有高度未满足医疗需求的疾病，首先是从帕金森病（PD）的自体神经元替代开始。

Aspen combines cell biology with the latest machine learning and genomic approaches to investigate patient-specific, restorative cell treatments. The company has developed a best-in-class platform to create and optimize pluripotent-derived cell therapies, which includes in-house bioinformatics, manufacturing and quality control.

Aspen结合细胞生物学与最新的机器学习和基因组学方法，研究针对患者的修复性细胞治疗。该公司开发了一个领先的平台，用于创建和优化多能干细胞衍生的细胞疗法，其中包括内部生物信息学、制造和质量控制。

For more information and important updates, please visit .

如需更多信息和重要更新，请访问 。

https://www.aspenneuroscience.com

https://www.aspenneuroscience.com

or email

或电子邮件

media@aspenneuroscience.com

媒体@阿斯彭神经科学.com

.

。

*

*

The study was made possible by funding from the California Institute for Regenerative Medicine (CIRM), a state of California Agency that funds regenerative medicine, stem cell, and gene therapy research (Grant Number CLIN2-15547).

本研究得以实现，得益于加州再生医学研究所（CIRM）的资助，该机构是加州的一个机构，负责资助再生医学、干细胞和基因治疗研究（资助编号 CLIN2-15547）。

SOURCE Aspen Neuroscience, Inc.

来源：Aspen Neuroscience, Inc.

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用